

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy Automated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood Pressure

Table of Contents

- Policy: Commercial
 - Authorization Information
- **Description**

Policy History

- Information Pertaining to All Policies
- References

<u>Coding Information</u>

Policy Number: 206

BCBSA Reference Number: 1.01.02 (For Plan internal use only)

Related Policies

None

Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Automated ambulatory blood pressure (BP) monitoring over a 24-hour period may be considered <u>MEDICALLY NECESSARY</u> for individuals with elevated office BP, when performed 1 time to differentiate between "white coat hypertension" and true hypertension, and when the following conditions are met:

- Office BP elevation is in the mild to moderate range (<180/110), not requiring immediate treatment with medications; and
- There is an absence of hypertensive end-organ damage on physical examination and laboratory testing.

All other uses of ambulatory blood pressure monitoring for individuals with elevated office BP are considered **INVESTIGATIONAL**, including but not limited to repeated testing in individuals with persistently elevated office BP and monitoring of treatment effectiveness.

Prior Authorization Information

Inpatient

 For services described in this policy, precertification/preauthorization <u>IS REQUIRED</u> for all products if the procedure is performed <u>inpatient</u>.

Outpatient

• For services described in this policy, see below for products where prior authorization <u>might be</u> <u>required</u> if the procedure is performed <u>outpatient</u>.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .

Commercial PPO and Indemnity	Prior authorization is not required .
------------------------------	--

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above <u>medical necessity criteria MUST</u> be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

CPT Codes

CPT codes:	Code Description
93784	Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; including recording, scanning analysis, interpretation and report
93786	Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; recording only
93788	Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; scanning analysis with report
93790	Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; review with interpretation and report
99473	Self-measured blood pressure using a device validated for clinical accuracy; patient education/training and device calibration
99474	Self-measured blood pressure using a device validated for clinical accuracy; separate self-measurements of two readings one minute apart, twice daily over a 30- day period (minimum of 12 readings), collection of data reported by the patient and/or caregiver to the physician or other qualified health care professional, with report of average systolic and diastolic pressures and subsequent communication of a treatment plan to the patient

Description

Typically done over a 24-hour period with a fully automated device, ambulatory blood pressure monitoring (ABPM) provides more detailed blood pressure (BP) information than readings typically obtained during office visits. The greater number of readings with ABPM ameliorates the variability of single BP measurements and is more representative of the circadian rhythm of BP. Various BP indices can be derived from the detailed BP information provided by ABPM, including multiple measure times (eg, 24 hours, daytime, nighttime) and dipping ratio (ie, calculated by dividing nighttime by daytime systolic BP). Studies evaluating the comparative clinical utility of the various available ABPM BP indices have suggested that higher 24-hour and nighttime BP indices may marginally improve model predictions of greater risk of death and composite cardiovascular events.¹

Ambulatory blood pressure monitoring has a number of potential applications. One of the most common is evaluating suspected white coat hypertension, which is defined as an elevated office BP with normal BP readings outside the physician's office. The etiology of white coat hypertension is poorly understood but may be related to an "alerting" or anxiety reaction associated with visiting the physician's office.

In assessing patients with elevated office BP, ABPM is often intended to identify those with normal ambulatory readings who do not have sustained hypertension. Because this group of patients would otherwise be treated based on office BP readings alone, ABPM could improve outcomes by allowing these patients to avoid unnecessary treatment. However, this assumes patients with white coat hypertension are not at increased risk for cardiovascular events and would not benefit from antihypertensive treatment.

Other uses of ABPM include monitoring patients with established hypertension under treatment; evaluating refractory or resistant BP; evaluating whether symptoms such as lightheadedness correspond with BP changes; evaluating night-time BP; examining diurnal patterns of BP; and other potential uses.

This evidence review does not directly address other uses of ABPM, including its use for the evaluation of "masked" hypertension. Masked hypertension refers to normal BP readings in the office and elevated BP readings outside of the office. This phenomenon has recently received greater attention, with estimates that up to 10% to 20% of individuals may exhibit this pattern.

Summary

Description

Ambulatory blood pressure (BP) monitors (24-hour sphygmomanometers) are portable devices that continually record BP while the patient is involved in daily activities. There are various types of ambulatory monitors; this evidence review addresses fully automated monitors, which inflate and record BP at preprogrammed intervals. Ambulatory blood pressure monitoring (ABPM) has the potential to improve the accuracy of diagnosing hypertension and thus improve the appropriateness of medication treatment.

Summary of Evidence

For individuals with elevated office blood pressure (BP) who receive 24-hour automated ambulatory blood pressure monitoring (ABPM), the evidence includes randomized controlled trials (RCTs), cohort studies, and studies of diagnostic accuracy. Relevant outcomes are test accuracy, other test performance measures, morbid events, and medication use. Data from large prospective cohort studies have established that ABPM correlates more strongly with cardiovascular outcomes than with other methods of BP measurement. Compared directly with other methods, ABPM performed over a 24-hour period has higher sensitivity, specificity, and predictive value for the diagnosis of hypertension than office or home BP measurements. Substantial percentages of patients with elevated office BP have normal BP on ABPM. Prospective cohort studies have reported that patients with white coat hypertension (WCH) have an intermediate risk of cardiovascular outcomes compared with normotensive and hypertensive patients. The benefit of medication treatment in these patients is uncertain, and they are at risk of overdiagnosis and over treatment based on office BP measurements alone. Use of automated ABPM in these patients will improve outcomes by eliminating unnecessary pharmacologic treatment and avoiding adverse events in patients not expected to benefit. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Date	Action
9/2024	Annual policy review. Policy updated with literature review through May 17, 2024;
	references added. Minor editorial refinements to policy statements; intent unchanged.
8/2023	Annual policy review. References updated. Policy statements unchanged.
9/2022	Annual policy review. Minor editorial refinements to policy statements; intent
	unchanged.
8/2021	Annual policy review. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for
	local coverage determination and national coverage determination reference.
8/2020	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
1/2020	Clarified coding information.

Policy History

8/2019	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
7/2018	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
7/2017	Annual policy review. New references added.
8/2016	Annual policy review. New references added.
11/2015	Clarified coding information.
3/2015	Annual policy review. New references added.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes. Effective
	10/2015.
4/2014	Annual policy review. New references added.
11/2013	New medically necessary indications described. Effective 11/1/2013.
11/2011	Medical policy ICD10 remediation: Formatting, editing and coding updates. No
-4/2012	changes to policy statements.
4/2011	Reviewed - Medical Policy Group – Cardiology and Pulmonology. No changes to policy
	statements.
4/2010	Reviewed - Medical Policy Group - Cardiology. No changes to policy statements.
4/2009	Reviewed - Medical Policy Group – Cardiology. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

Medical Policy Terms of Use Managed Care Guidelines Indemnity/PPO Guidelines Clinical Exception Process Medical Technology Assessment Guidelines

References

- 1. Yang WY, Melgarejo JD, Thijs L, et al. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. Aug 06 2019; 322(5): 409-420. PMID 31386134
- Food and Drug Administration (FDA). Welch Allyn ABPM 1600 pre-market notification: 510(k) summary. 2002; https://www.accessdata.fda.gov/cdrh_docs/pdf2/K021756.pdf. Accessed May 16, 2024.
- Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). 24-hour ambulatory blood pressure monitoring for the evaluation of patients with elevated office blood pressure. TEC Assessments. 1999;Volume 14:Tab 8.
- 4. LeFevre F, Aronson N. Technology assessment for ambulatory blood pressure monitoring for adults with elevated office blood pressure decision memo. October 17, 2001; https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=5&NCDId=254. Accessed May 17, 2024.
- Imai Y, Hozawa A, Ohkubo T, et al. Predictive values of automated blood pressure measurement: what can we learn from the Japanese population - the Ohasama study. Blood Press Monit. Dec 2001; 6(6): 335-9. PMID 12055412
- 6. Verdecchia P. Reference values for ambulatory blood pressure and self-measured blood pressure based on prospective outcome data. Blood Press Monit. Dec 2001; 6(6): 323-7. PMID 12055410
- Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ. Apr 14 2010; 340: c1104. PMID 20392760
- 8. Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. Apr 24 2007; 115(16): 2145-52. PMID 17420350
- Staessen JA, Beilin L, Parati G, et al. Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit. Dec 1999; 4(6): 319-31. PMID 10602536

- Muntner P, Lewis CE, Diaz KM, et al. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. May 2015; 28(5): 640-8. PMID 25376639
- 11. Martin U, Haque MS, Wood S, et al. Ethnicity and differences between clinic and ambulatory blood pressure measurements. Am J Hypertens. Jun 2015; 28(6): 729-38. PMID 25398890
- Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. Jun 01 2006; 354(22): 2368-74. PMID 16738273
- 13. Staessen JA, Asmar R, De Buyzere M, et al. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit. Dec 2001; 6(6): 355-70. PMID 12055415
- Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens. Aug 2007; 25(8): 1554-64. PMID 17620947
- 15. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. Jul 2008; 26(7): 1290-9. PMID 18550999
- Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. Feb 03 2015; 162(3): 192-204. PMID 25531400
- 17. Panagiotakos D, Antza C, Kotsis V. Ambulatory and home blood pressure monitoring for cardiovascular disease risk evaluation: a systematic review and meta-analysis of prospective cohort studies. J Hypertens. Jan 01 2024; 42(1): 1-9. PMID 37702566
- Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. Jun 24 2011; 342: d3621. PMID 21705406
- 19. Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. Am J Hypertens. Feb 2011; 24(2): 123-34. PMID 20940712
- Stergiou GS, Karpettas N, Panagiotakos DB, et al. Comparison of office, ambulatory and home blood pressure in children and adolescents on the basis of normalcy tables. J Hum Hypertens. Apr 2011; 25(4): 218-23. PMID 20520632
- 21. Urbina E, Alpert B, Flynn J, et al. Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension. Sep 2008; 52(3): 433-51. PMID 18678786
- 22. Valent-Morić B, Zigman T, Zaja-Franulović O, et al. The importance of ambulatory blood pressure monitoring in children and adolescents. Acta Clin Croat. Mar 2012; 51(1): 59-64. PMID 22920003
- 23. Sorof JM, Portman RJ. White coat hypertension in children with elevated casual blood pressure. J Pediatr. Oct 2000; 137(4): 493-7. PMID 11035827
- 24. Matsuoka S, Kawamura K, Honda M, et al. White coat effect and white coat hypertension in pediatric patients. Pediatr Nephrol. Nov 2002; 17(11): 950-3. PMID 12432440
- 25. National High Blood Pressure Education Program (NHBPEP). Working Group Report on Ambulatory Blood Pressure Monitoring (NIH Publication No. 92-3028). Bethesda, MD: Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1992.
- Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. Sep 05 2000; 102(10): 1139-44. PMID 10973843
- 27. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. Sep 2017; 140(3). PMID 28827377
- 28. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. May 15 2018; 71(19): 2199-2269. PMID 29146533

- Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. May 2014; 63(5): 1116-35. PMID 24591341
- Flynn JT, Urbina EM, Brady TM, et al. Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association. Hypertension. Jul 2022; 79(7): e114-e124. PMID 35603599
- Muntner P, Shimbo D, Carey RM, et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. May 2019; 73(5): e35-e66. PMID 30827125
- 32. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management [NG136]. 2019; https://www.nice.org.uk/guidance/ng136. Accessed May 17, 2024.
- 33. U.S. Preventive Services Task Force. Screening for Hypertension in Adults. 2021; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adultsscreening. Accessed May 15, 2024.
- 34. Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Nov 17 2015; 163(10): 778-86. PMID 26458123
- Krist AH, Davidson KW, Mangione CM, et al. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. Apr 27 2021; 325(16): 1650-1656. PMID 33904861
- 36. U.S. Preventive Services Task Force. High Blood Pressure in Children and Adolescents: Screening. 2020; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/blood-pressure-in-children-and-adolescents-hypertension-screening. Accessed May 16, 2024.
- Gartlehner G, Vander Schaaf EB, Orr C, et al. Screening for Hypertension in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. Nov 10 2020; 324(18): 1884-1895. PMID 33170247
- 38. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Ambulatory Blood Pressure Monitoring [20.19]. 2019; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=254. Accessed May 17, 2024.